



Comprehensive Guidelines for the Safe Administration of Total Parenteral Nutrition (TPN) in Surgical and Critically Ill Patients

Kerellos Shoukeir, Tarek Eltantawy and Ramy Aly

FRCS plast, MSc, MRCS, MB.BCH
Email: rmsmmaly@hotmail.com

Manuscript details:

Received: 18.07.2024
Accepted: 24.08.2024
Published: 30.09.2024

Cite this article as:

Kerellos Shoukeir, Tarek Eltantawy and Ramy Aly (2024) Comprehensive Guidelines for the Safe Administration of Total Parenteral Nutrition (TPN) in Surgical and Critically Ill Patients, *Int. J. of Life Sciences*, 12 (3): 279-282.

Available online on <http://www.ijlsci.in>
ISSN: 2320-964X (Online)
ISSN: 2320-7817 (Print)



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

ABSTRACT

Total Parenteral Nutrition (TPN) is a vital therapeutic intervention for patients who cannot achieve adequate nutrition enterally. This paper provides comprehensive guidelines for the initiation, advancement, and monitoring of TPN, aiming to minimise complications such as hyper glycaemia, infections, and metabolic disturbances. The guidelines are based on an extensive review of current literature and clinical best practices, offering a structured approach to optimise patient outcomes through meticulous planning and proactive management.

Keywords: Total Parenteral Nutrition (TPN), Surgical nutrition, Bone Disease.

BACKGROUND

TPN is indispensable for patients unable to meet their nutritional needs via the gastrointestinal tract, particularly in surgical and critically ill populations. Despite its benefits, TPN administration presents significant risks, including metabolic derangements, catheter-related infections, and liver dysfunction. Effective TPN management necessitates a structured approach to initiation, advancement, and continuous monitoring to minimise these risks and ensure optimal patient outcomes. This paper consolidates current best practices and provides detailed guidelines for the safe and effective administration of TPN.

METHODS

This study synthesises data from current literature, clinical trials, and expert consensus to develop evidence-based guidelines for TPN administration. The methodology includes:

Literature Review: Comprehensive review of existing studies, guidelines, and clinical trials on TPN administration and its complications.

Expert Consensus: Consultation with clinical nutrition experts to validate the guidelines and incorporate practical insights.

Structured Protocol Development: Formulation of detailed protocols for the phased initiation and advancement of TPN, continuous metabolic monitoring, and proactive management of potential complications.

RESULTS

Initiation and Advancement Schedule

Day 1:

- **Solution Composition:** Initiate with a starter solution containing 70 g amino acids and 150 g dextrose in 1000 mL.
- **Monitoring:** Assess blood glucose every 6 hours and electrolytes daily. Monitor for signs of volume overload and adverse reactions to the infusion.

Day 2:

- **Solution Advancement:** If tolerated, advance to a solution with 70 g amino acids and 210 g dextrose.
- **Continuous Monitoring:** Continue frequent blood glucose checks and daily electrolyte monitoring.

Day 3 and Beyond:

- **Protein and Dextrose Adjustment:** Increase protein to goal levels and advance dextrose gradually toward target amounts by increments of 50-100 g/day.
- **Lipid Addition:** Introduce lipids if desired and as tolerated.
- **Glycemic Control:** If blood sugar levels exceed 150 mg/dL, do not increase dextrose content until glycemic control is achieved.

Monitoring and Adjustment

Glucose Management:

- **Importance:** Maintaining glycemic control is crucial to prevent infections and other complications.
- **Frequency:** Tailor glucose monitoring frequency to patient stability—hourly in unstable patients, thrice daily in stable patients.
- **Interventions:** Administer insulin as needed based on a sliding scale and adjust TPN composition to avoid excessive carbohydrate load.

Lipid Administration:

- **Composition:** Use lipid emulsions with reduced n-6 PUFA content to lower the risk of inflammation.
- **Monitoring:** Regularly monitor triglyceride levels to prevent hypertriglyceridemia.
- **Safe Dosage:** Administer lipids up to 2 g/kg/day, keeping within safe triglyceride levels.

Amino Acid Supplementation:

- **Essential Amino Acids:** Ensure adequate levels of glutamine and arginine to support immune function and bowel health.
- **Dosage:** Administer amino acids at 1.2-1.5 g/kg/day, adjusting based on patient needs and metabolic response.

Vitamins and Trace Elements:

- **Daily Requirements:** Include a full range of vitamins and trace elements in the TPN solution to prevent deficiencies.
- **Adjustment:** Modify based on periodic assessments of patient status and laboratory results.

Complications Management

Catheter-related Complications:

- **Prevention:** Use proper insertion techniques and aseptic protocols to reduce risks of misplacement, pneumothorax, thrombosis, and infection.
- **Management:** Treat complications promptly with appropriate interventions such as antibiotics for infections or anticoagulants for thrombosis.

Metabolic Complications:

- **Electrolyte Imbalances:** Monitor and correct sodium, potassium, magnesium, and phosphate levels regularly.
- **Hyperglycemia:** Address with insulin administration and adjustments to TPN composition.
- **Re feeding Syndrome:** Monitor for signs such as hypophosphatemia and treat with appropriate electrolyte supplementation.

Hepatic Dysfunction:

- **Causes:** Often related to the long-chain fatty acids in TPN; monitor liver function tests regularly.
- **Management:** Use mixed emulsions containing medium-chain triglycerides to reduce the risk of cholestasis and fatty liver.

Metabolic Bone Disease:

- **Risk Factors:** Long-term TPN can lead to decreased bone mineral density.
- **Prevention:** Include adequate calcium and vitamin D in TPN and monitor bone health periodically.

DISCUSSION

The phased approach to TPN initiation and advancement ensures that the nutritional needs of patients are met while minimising the risk of metabolic derangements. Continuous monitoring and proactive management of complications are critical to maintaining patient safety and optimising outcomes. Glucose management is particularly important, as hyperglycemia is associated with increased morbidity and mortality in TPN patients. Regular monitoring of lipid levels, amino acid balance, and vitamins and trace elements is also essential to prevent deficiencies and other complications.

The guidelines emphasise the importance of individualised care, as patient responses to TPN can vary widely. Tailoring the TPN regimen to each patient's needs, based on continuous assessment and monitoring, is crucial. The management of catheter-related complications and the prevention of re feeding syndrome are also highlighted as key areas for intervention.

CONCLUSION

Comprehensive guidelines for TPN administration can significantly improve patient outcomes. By following a structured approach to initiation, advancement, and monitoring, and by addressing complications proactively, healthcare providers can deliver TPN safely and effectively. Continued research and adherence to best practices are essential for optimising TPN therapy and enhancing patient care in surgical and critically ill populations.

REFERENCES

Alivizatos V, Felekis D, Zorbalas A. Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas. *Hepatogastro- enterology*. Jul-Aug 2002; 49(46): 1010-2.

- Al-Jurf, Adel S. and Karen D. Indications for Total Parenteral Nutrition (TPN)." University of Iowa Virtual Hospital. March 2003.
- Baines M, Shenkin A. Lack of effectiveness of short-term intravenous micronutrient nutrition in restoring plasma antioxidant status after surgery. *Clin Nutr* 2002;21:145-50.
- Cagir B., Sawyer M.: Nutritional management of short bowel syndrome in adults. *ESPEN Guidelines on Parenteral Nutrition: gastroenterology*. *Clin Nutr*. Sep 2009 emedicine.medscape.com/article/193391
- Calder PC. Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. *Braz J Med Biol Res* 2003;36:433-46.
- Gillanders L., Angstmann K., Nurs. B., Ball P., Chapman C., Hardy G., Hope J., Smith R., Strauss B., and Russell D.: AuSPEN clinical practice guideline for home parenteral nutrition patients in Australia and New Zealand. *Nutrition* 2008; 24: 998-1012.
- Glasgow S. and Herrmann V.: Nutrition. In: Klingensmith, Mary E.; Amos, Keith D.; Green, Douglas W.; Halpin, Valerie J.; Hunt, Steven R. (eds) *Washington manual of surgery* 4th ed, 2005; ch.2: 36-52.
- Hesse U, Ysebaert D, de Hemptinne B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. *Gut* 2001; 49(Suppl 4): iv11-iv21.
- Ioannidis O., Lavrentieva A., Botsios D.: the ESPEN guidelines for nutrition support in acute pancreatitis. *J Pancreas (Online)* 2008; 9(4):375-390.
- Jacobs DO. Bioelectrical impedance analysis: implications for clinical practice. *Nutr Clin Pract* 1997;12:204-10.
- Jagoe RT, Goldberg AL: What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?. *Curr Opin Clin Nutr Metab Care* 2001; 4:183-190.
- Krishnan JA, Parce PB, Martinez A, Diette GB, Brower RG. Caloric intake in medical ICU patients: consistency of care with guidelines and relationship to clinical outcomes. *Chest* 2003;124:297-305
- Kumar A, Singh N, Prakash S, Saraya A, Joshi YK. Early enteral nutrition in severe acute pancreatitis: a prospective randomized controlled trial comparing nasojejunal and nasogastric routes. *J Clin Gastroenterol* 2006; 40:431-4
- Le Banh : Serum Proteins as Markers of Nutrition: What Are We Treating? *Practical Gastroenterology* 2006; 43:46-57.
- Lloyd D., Gabe S. and Windsor A. Nutrition and management of enterocutaneous fistula. *British Journal of Surgery* 2006; 93: 1045-1055.
- Lofberg E, Gutierrez A, Wernerman J, et al: Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. *Eur J Clin Invest* 2002; 32:345-353.
- Lorite MJ, Smith HJ, Arnold JA, et al: Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). *Br J Cancer* 2001; 85:297-302.

- Luiking YC, Deutz NE. Exogenous arginine in sepsis. *Crit Care Med* 2007;35: S557–63
- Lynch AC, Delaney CP, Senagore AJ, Connor JT, Remzi FH, Fazio VW. Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery. *Ann Surg* 2004; 240: 825–831.
- Medeiros AC, Aires-Neto T, Marchini JS, Brandao-Neto J, Valenca DM, Egito ES. Treatment of postoperative enterocutaneous fistulas by high-pressure vacuum with a normal oral diet. *Dig Surg* 2004; 21: 401–405
- Stroud M., Duncan H. and Nightingale J.: Guidelines for Enteral Feeding in Adult Hospital Patients. *Gut* 2003; 52: vii 1-12.
- Zheng YM, Li F, Zhang MM, Wu XT.: Glutamine dipeptide for parenteral nutrition in abdominal surgery; a meta-analysis of randomized controlled trials. *World J Gastroenterol* 2006;12:7537–41.

© The Authors 2024

Conflict of interest: The authors declare that they have no conflict of interest.

Authors contribution

Kerellos Shoukeir : Designed the study, Collected patient data

Tarek Tantawy : Writing the Manuscript.

Ramy Aly : Editing and reviewing the Manuscript, critically revised final edition. Reviewed literature and analysis of data,

Ethical approval :

NONE

Source of Funding :

None

Publisher’s Note

IJLSCI remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Correspondence and requests for materials should be addressed to Paula Lozano.

Peer review information

IJLSCI thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <https://www.ijlsci.in/reprints>

Submit your manuscript to a IJLSCI journal and benefit from:

- ✓ Convenient online submission
- ✓ Rigorous peer review
- ✓ Immediate publication on acceptance
- ✓ Open access: articles freely available online
- ✓ High visibility within the field

Submit your next manuscript to IJLSCI through our manuscript management system uploading at the menu "Make a Submission" on journal website

Email your next manuscript to IJLSCI
editor@ijlsci.in
